2 research outputs found

    The Effects of Age, Resilience, and Fraud Victimization on Mental Health During the Second Year of the COVID-19 Pandemic

    Get PDF
    During the height of the pandemic, COVID-19 threatened the physical, financial, and social wellbeing of people worldwide through work-from-home, quarantine, and isolation policies. Subsequently, the pandemic years have been linked to increases in reported loneliness, negative emotionality, depression, anxiety, and suicidal ideation (e.g., Finch et al., 2022; O’Sullivan et al., 2021; WHO, 2022). Although trait resilience and other resources such as social support helped to ease the negative emotional impact of the pandemic, they may have been insufficient to fully negate pandemic-related mental health challenges (Coloumbe et al., 2020; García-Rivera et al., 2021). In fact, those who experienced more pandemic-related fear and uncertainty have described lower levels of psychological resilience to draw on when coping with their poor mental health (García-Rivera et al., 2021). Resilience is defined as the ability to adapt to and recover from challenges such as living through the COVID-19 pandemic

    Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Get PDF
    Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome
    corecore